Both the Fab and Fc domains of IgG are essential for ROS emission from TNF-α-primed neutrophils by IVIG

Biochemical and Biophysical Research Communications

Volumn 417, Issue 2, 2012, Pages 794-799

  Higurashi, Saki ^a   Machino, Yusuke ^a   Suzuki, Emiko ^a   Suzuki, Mami ^a   Kohroki, Junya ^a,b   Masuho, Yasuhiko ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Fc receptor; Intravenous immunoglobulin; Neutrophil; Reactive oxygen species; Untoward reactions

Indexed keywords

CD16 ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL ACTIVATION; HUMAN; HUMAN CELL; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL; PURIFICATION;

CELLS, CULTURED; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULINS, INTRAVENOUS; NEUTROPHILS; REACTIVE OXYGEN SPECIES; RESPIRATORY BURST; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855825620     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.12.038     Document Type: Article

References (34)

1. Imbach P., Barandun S., d'Apuzzo V., Baumgartner C., Hirt A., Morell A., Rossi E., Schöni M., Vest M., Wagner H.P. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981, 1:1228-1231.
2. Steele R.W., Jr Burks A.W., Williams L.W. Intravenous immunoglobul new clinical applications. Ann. Allergy 1988, 60:89-94.
3. Kleyweg R.P., van der Meché F.G., Meulstee J. Treatment of Guillain-Barré syndrome with high-dose gammaglobulin. Neurology 1988, 38:1639-1641.
4. Lemieux R., Bazin R., Neron S. Therapeutic intravenous immunoglobulins. Mol. Immunol. 2005, 42:839-848.
5. Stangel M., Hartung H.P., Marx P., Gold R. Side effects of high-dose intravenous immunoglobulins. Clin. Neuropharmacol. 1997, 20:385-393.
6. Sherer Y., Levy Y., Langevitz P., Rauova L., Fabrizzi F., Shoenfeld Y. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology 2001, 62:133-137.
7. Stangel M., Kiefer R., Pette M., Smolka M.N., Marx P., Gold R. Side effects of intravenous immunoglobulins in neurological autoimmune disorders -a prospective study. J. Neurol. 2003, 250:818-821.
8. Voltz R., Rosen F.V., Yousry T., Beck J., Hohlfeld R. Reversible encephalopathy with cerebral vasospasm in a Guillain-Barré syndrome patient treated with intravenous immunoglobulin. Neurology 1996, 46:250-251.
9. Silbert P.L., Knezevic W.V., Bridge D.T. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 1992, 42:257-258.
10. Sekul E.A., Cupler E.J., Dalakas M.C. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann. Intern. Med. 1994, 121:259-262.
11. De Vlieghere F.C., Peetermans W.E., Vermylen J. Aseptic granulocytic meningitis following treatment with intravenous immunoglobulin. Clin. Infect. Dis. 1994, 18:1008-1010.
12. Takai T. Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 2002, 2:580-592.
13. Nimmerjahn F., Ravetch J.V. Fcgamma receptors: old friends and new family members. Immunity 2006, 24:19-28.
14. Sugita K., Hirao J., Arisaka O., Eguchi M. Gamma-globulin-induced modulation with necrotic-like morphology of peripheral blood neutrophils. Eur. J. Pharmacol. 2005, 513:141-144.
15. Dooren M., Ouwehand W., von Verhoeven A., dem Borne A., Kuijpers R. Adult respiratory distress syndrome after experimental intravenous γ-globulin concentrate and monocyte-reactive IgG antibodies. Lancet 1998, 352:1601-1602.
16. Teeling J.L., De Groot E.R., Eerenberg A.J., Bleeker W.K., Van Mierlo G., Aarden L.A., Hack C.E. Human intravenous immunoglobulin (IVIG) preparations degranulate human neutrophils in vitro. Clin. Exp. Immunol. 1998, 114:264-270.
17. Nemes E., Teichman F., Roos D., Maródi L. Activation of human granulocytes by intravenous immunoglobulin preparations is mediated by FcgammaRII and FcgammaRIII receptors. Pediatr. Res. 2000, 47:357-361.
18. Rousseaux J., Rousseaux-Prévost R., Bazin H. Optimal conditions for the preparation of Fab and F(ab')2 fragments from monoclonal IgG of different rat IgG subclasses. J. Immunol. Methods 1983, 64:141-146.
19. Edberg J.C., Kimberly R.P. Modulation of Fc gamma and complement receptor function by the glycosyl-phosphatidylinositol-anchored form of Fc gamma RIII. J. Immunol. 1994, 152:5826-5835.
20. Wymann S., Ghielmetti M., Schaub A., Baumann M.J., Stadler B.M., Bolli R., Miescher S.M. Monomerization of dimeric IgG of intravenous immunoglobulin (IVIg) increases the antibody reactivity against intracellular antigens. Mol. Immunol. 2008, 45:2621-2628.
21. Bleeker W.K., Teeling J.L., Hack C.E. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood 2001, 98:3136-3142.
22. Ahn S.Y., Jang G.C., Shin J.S., Shin K.M., Kim D.S. Tumor necrosis factor-alpha levels and promoter polymorphism in patients with Kawasaki disease in Korea, Yonsei. Med. J. 2003, 44:1021-1026.
23. Radhakrishnan V.V., Sumi M.G., Reuben S., Mathai A., Nair M.D. Serum tumour necrosis factor-alpha and soluble tumour necrosis factor receptors levels in patients with Guillain-Barre syndrome. Acta Neurol. Scand. 2004, 109:71-74.
24. Ewert B.H., Jennette J.C., Falk R.J. Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int. 1992, 41:375-383.
25. Savage C.O., Pottinger B.E., Gaskin G., Pusey C.D., Pearson J.D. Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. Am. J. Pathol. 1992, 141:335-342.
26. Mirshafiey A., Mohsenzadegan M. The role of reactive oxygen species in immunopathogenesis of rheumatoid arthritis, Iran. J. Allergy Asthma Immunol. 2008, 7:195-202.
27. Machino Y., Ohta H., Suzuki E., Higurashi S., Tezuka T., Nagashima H., Kohroki J., Masuho Y. Effect of immunoglobulin G (IgG) interchain disulfide bond cleavage on efficacy of intravenous immunoglobulin for immune thrombocytopenic purpura (ITP). Clin. Exp. Immunol. 2010, 162:415-424.
28. Lacroix-Desmazes S., Kaveri S.V., Mouthon L., Ayouba A., Malanchère E., Coutinho A., Kazatchkine M.D. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J. Immunol. Methods 1998, 216:117-137.
29. Jarius S., Eichhorn P., Albert M.H., Wagenpfeil S., Wick M., Belohradsky B.H., Hohlfeld R., Jenne D.E., Voltz R. Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFalpha-dependent and Fc-receptor-independent way. Blood 2007, 109:4376-4382.
30. Kettritz R., Jennette J.C., Falk R.J. Crosslinking of ANCA-antigens stimulates superoxide release by human neutrophils. J. Am. Soc. Nephrol. 1997, 8:386-394.
31. Mulder A.H., Heeringa P., Brouwer E., Limburg P.C., Kallenberg C.G. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-dependent process. Clin. Exp. Immunol. 1994, 98:270-278.
32. Reumaux D., Vossebeld P.J., Roos D., Verhoeven A.J. Effect of tumor necrosis factor-induced integrin activation on Fc gamma receptor II-mediated signal transduction: relevance for activation of neutrophils by anti-proteinase 3 or anti-myeloperoxidase antibodies. Blood 1995, 86:3189-3195.
33. 2+ response in human neutrophils. J. Biol. Chem. 1995, 270:10671-10679.
34. Durandy A., Kaveri A.V., Kuijpers T.W., Basta M., Miescher S., Ravetch J.V., Rieben R. Intravenous immunoglobulins--understanding properties and mechanisms. Clin. Exp. Immunol. 2009, 158:2-13.